Core Insights - The stock of Huaren Health increased by 1.44% on October 31, with a trading volume of 70.71 million yuan [1] - The company reported a net financing outflow of 5.09 million yuan on the same day, with a total financing and securities balance of 122 million yuan [1] - Huaren Health's main business revenue consists of 97.60% from traditional Chinese and Western medicine, and 2.40% from other sources [1] Financing and Margin Trading - On October 31, Huaren Health had a financing buy-in of 5.65 million yuan, with a current financing balance of 122 million yuan, representing 6.07% of its market capitalization [1] - The financing balance is above the 70th percentile of the past year, indicating a relatively high level [1] - There were no short sales or repayments on the same day, with a short balance of 1342 yuan, which is below the 50th percentile of the past year [1] Financial Performance - For the period from January to September 2025, Huaren Health achieved a revenue of 3.892 billion yuan, reflecting a year-on-year growth of 19.06% [2] - The net profit attributable to shareholders for the same period was 157 million yuan, showing a year-on-year increase of 45.21% [2] Shareholder Information - As of September 30, 2025, the number of Huaren Health shareholders was 20,100, a decrease of 22.86% from the previous period [2] - The average number of circulating shares per shareholder increased by 29.64% to 7,422 shares [2] - The company has distributed a total of 80.02 million yuan in dividends since its A-share listing [3] - Hong Kong Central Clearing Limited is the fifth-largest circulating shareholder, holding 2.3203 million shares, an increase of 1.3357 million shares from the previous period [3]
华人健康10月31日获融资买入564.77万元，融资余额1.22亿元